Important update for our previously treated metastatic pancreatic cancer (PDAC) patients:
Date 4.5.2026 Time 15:15, written by Nir Erez
Revolution Medicines received FDA authorization to open an Expanded Access Program (EAP) for the investigational drug Daraxonrasib (also known as RMC-6236), a RAS(ON) inhibitor.
Who is this for?
For previously treated metastatic pancreatic cancer patients who have a KRAS G12 mutation:
- Are ineligible or unable to participate in a Revolution Medicines clinical trial, and
- Do not have satisfactory alternative treatment options.
Important details:
The drug will be provided at no cost to eligible patients.
Only a licensed treating physician can submit a request.
What to do now?
👈🏼 Contact your treating oncologist immediately.
👈🏼 Ask them to submit an EAP request for Daraxonrasib (RMC-6236) to the email: medinfo@revmed.com
👈🏼 To increase the chances of approval, ask the doctor to clearly state the two points in the request:
- You are ineligible or unable to participate in a Revolution Medicines clinical trial,
- You do not have satisfactory alternative treatment options.
👈🏼 Send your treating oncologist the following links:
Important note:
The company reviews each request individually and at its sole discretion, and does not commit to approving every request.
It aims to respond to requests within 2 business days.
The company reviews each request individually and at its sole discretion, and does not commit to approving every request.
It aims to respond to requests within 2 business days.
If you have questions – write to us
Of course, update us on any development, we are here with you and for you
Sending you much strength 💪❤️
Of course, update us on any development, we are here with you and for you
Sending you much strength 💪❤️
